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Abstract
Background: Effects of increased adenosine dose in the assessment of fractional flow reserve (FFR) were studied in
relation to FFR results, hemodynamic effects and patient discomfort. FFR require maximal hyperemia mediated by
adenosine. Standard dose is 140 μg/kg/min administrated intravenously. Higher doses are commonly used in clinical
practice, but an extensive comparison between standard intravenous dose and a high dose (220 μg/kg/min) has
previously not been performed.
Methods: Seventy-five patients undergoing FFR received standard dose adenosine, followed by high dose adenosine.
FFR, mean arterial pressure (MAP) and heart rate (HR) were analyzed. Patient discomfort measured by Visual Analogue
Scale (VAS) was assessed.
Results: No significant difference was found between the doses in FFR value (0.85 [0.79–0.90] vs 0.85 [0.79–0.89],
p = 0.24). The two doses correlated well irrespective of lesion severity (r = 0.86, slope = 0.89, p = <0.001). There were no
differences in MAP or HR. Patient discomfort was more pronounced using high dose adenosine (8.0 [5.0–9.0]) versus
standard dose (5.0 [2.0–7.0]), p = <0.001.
Conclusions: Increased dose adenosine does not improve hyperemia and is associated with increased patient
discomfort. Our findings do not support the use of high dose adenosine.
Trial registration: Retrospective Trial registration: Current Controlled Trials ISRCTN14618196. Registered 15
December 2016.
Keywords: Coronary heart disease, Fractional flow reserve, Adenosine, Visual analogue scale
Background
Fractional Flow Reserve (FFR) is the most validated diag-
nostic method to determine physiologically significance of
stenosis in the epicardial arteries [1–4]. FFR is defined as
the ratio of pressure difference across a coronary lesion
during hyperemia [5]. The use of FFR-guidance in percu-
taneous coronary intervention (PCI) has been shown to
identify which lesions that benefit from revascularization
[2]. In addition, the use of FFR in PCI reduces the need of
repeat interventions, enhances quality of life and demon-
strates cost effectiveness [3]. FFR carries a strong guideline
recommendation (Class I, level of evidence A) [6].
The diagnostic accuracy of FFR in terms of identifica-
tion of stenosis with inducible ischemia is 85–93% [7–9].
The use of FFR and hence, diagnostic accuracy, requires
induction of maximal hyperemia in the coronary arteries
[10]. Different agents for induction of hyperemia have
been studied, where the most validated are adenosine
and papaverine [11, 12]. The purine nucleoside adeno-
sine is a potent vasodilator with short duration time,
why dosage in relation to hyperemic effect is unpredict-
able [13]. In addition, side effects such as hypotension,
bradyarrhytmias, respiratory distress and patient discom-
fort are common [14, 15]. Side effects, together with the
cost of adenosine, are considered reasons why the
utilization of FFR is still not according to guidelines
[16]. Alternatives to adenosine with less side effects of
vasodilatation have been suggested, for example the use
of non-ionic, radiocontrast medium which generates
submaximal hyperemia by osmosis [17, 18]. Also, other
techniques such as resting distal pressure (Pd)/aortic
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pressure (Pa) and the instantaneous wave-free ratio (iFR)
are under development [9].
Even though different agents and techniques may offer
alternative for future improvements, adenosine, adminis-
tered by an intravenous infusion of 140 μg/kg/min, re-
mains the golden standard [1, 3, 4, 10, 19].
The adequate dose and administration route of adeno-
sine have been questioned over the years. Previous trials
have shown equivalent FFR results by intracoronary
injections compared to intravenous infusion [20–23].
Furthermore, optimal dosage for adenosine administra-
tion remains unclear and studies have suggested that the
current standard dose may be insufficient to induce
maximal hyperemia [24–27]. In a previous smaller trial
investigating the effects of increased intravenous adeno-
sine, no benefit emerged from the high dose regime [18].
Nevertheless, it is still praxis to increase the hyperemic
agent in borderline cases [28]. Considering these dis-
crepancies between trial results and clinical traditions,
we wanted to determine if increased intravenous adeno-
sine improve diagnostics in a larger clinical population.
Also, the impact of patient co-morbidity such as chronic
kidney disease and diabetes [29], as well as different adeno-
sine antagonists, for example caffeine, has been investi-
gated. In recent trials, caffeine seems to attenuate the effect
of adenosine [30, 31]. Caffeine is a derived methylxanthine
acting as a competitive inhibitor of adenosine receptors A1
and A2A. Caffeine consumption prior to adenosine perfu-
sion diagnostics is therefore considered a relative contra-
indication [32–37].
The primary objective was to study the effects of
increased dose intravenous adenosine in FFR. Secondary
objectives were to study the hemodynamic effects and
patient discomfort of increased adenosine dose in patients
with or without caffeine consumption prior to FFR.
Methods
Design
The present study was a prospective, non-randomized
trial with an open-label design. The non-randomized
design was chosen since the patients constitute their
own controls. The lower dose was always administered
first in order to mimic clinical routine. The study was
conducted as a single-center, non-consecutive trial at
Skane University Hospital, Lund, Sweden. Patient admit-
ted for coronary angiography were considered eligible
for inclusion if the following criteria were fulfilled: Age
≥18 years, borderline-significant coronary stenosis (indi-
cation for FFR according to ESC Guidelines) [6] and
signed informed consent prior to enrollment. Key exclu-
sion criteria were allergy to adenosine or contrast media,
baseline mean arterial pressure <60 mmHg, baseline
heart rate <50, pharmacological treated asthma, chronic
obstructive pulmonary disease equivalent to GOLD
classification III and IV [38], confusion or inability to
comprehend the study information.
Procedure
Following coronary angiography and intracoronary ad-
ministration of 200 μg Nitroglycerin, a 0.014-inch pressure
guide wire (Primewire Prestige®/Verrata® Pressure Guide
Wire, Volcano Corporation, San Diego, CA, US) was
advanced through a 6-F guide catheter into the coronary
artery, calibrated and subsequently advanced distal of the
lesion. The infusion of intravenous adenosine (Adenosin
Life Medical 5 mg/ml, Life Medical Sweden AB) was
started at a weight-adjusted rate, equivalent to standard
dose 140 μg/kg/min and terminated when the two
minutes measurement was completed. The agent was ad-
ministrated through a peripheral intravenous line. FFR
was recorded for two minutes (±5 s) and calculated by the
Volcano CORE™ integrated system with the S5I® software
and Case Manager (Volcano Corporation, San Diego, CA,
US). Prior to the second measurement, a recovery time
was mandatory for the pressure curve to return to base-
line values (minimum 5 min). After recovery, the second
measurement was performed with similar FFR technique
and an intravenous adenosine infusion of 220 μg/kg/min.
FFR was considered significant if ≤0.80. The FFR results of
standard dose were used for clinical decision of revascu-
larization. A ≥0.02 drift of the FFR-wire was considered
clinical relevant, and if this occured, a new calibration was
performed. Consumption of caffeine was defined as a
minimum of 200 ml filter coffee consumed ≤6 h prior to
FFR. The patients coffee intake ranged between 200 and
400 ml.
Data collection
Mean arterial pressure (MAP) and heart rate were moni-
tored and collected at baseline and every 30 s during the
measurements (Philips Intellivue® Cardiac system, ver-
sion M8010A, Royal Philips Electronics, Amsterdam,
Netherlands). The patients were asked to score max-
imum discomfort following each measurement by a
validated tool for determination of pain/discomfort, the
Visual-Analogue-Scale (VAS) [39–41].
Sample size and statistical analysis
Based on standard deviations in FFR-measurements in
previous studies [24, 25], a sample size of 72 would have
a 90% power to detect a 15% difference of FFR with a
significance level (alpha) of 0.05% (two-tailed). In order
to compensate for loss of data due to a presumed inability
to tolerate high dose adenosine, the a priori number of pa-
tients intended to include was 85. The statistical analysis
was performed using the Graphpad Prism6™ for Mac OS
X™ (Graphpad Software Inc. La Jolla, CA, US). Continuous
variables were followed and reported as a mean ± standard
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deviation or as median (interquartile range 25–75) if asym-
metrically distributed. The correlation of adenosine doses
was calculated by Wilcoxon matched-pairs signed rank test
and a linear regression model. The agreement was graphic-
ally displayed in a Bland-Altman plot. In addition, for the
continuous hemodynamic variables of mean arterial pres-
sure and heart rate, an area under curve (AUC) analysis
was performed. The interference between the groups in the
caffeine analyses was based on the computation of the
Mann-Whitney U-test (Wilcoxon rank-sum-test) to deter-
mine significance. A p-value of <0.05 was considered statis-
tically significant.
Results
Patient characteristics and procedural data
Eighty-seven patients scheduled for FFR were included.
Ten patients (11%) developed atrioventricular block during
administration of standard dose adenosine and were
excluded from the second measurement and further ana-
lysis. Another 2 patients declined to participate in the
second measurement due to severe discomfort from adeno-
sine administration. Of the remaining 75 patients, two
complete FFR measurements within the same coronary
lesion using the two different dose regimens were per-
formed. Patient demographics and clinical characteristic are
presented in Table 1. In 28% of the cases, FFR was ≤0.80
after the first measurement and PCI were thus performed.
In the group treated by PCI, procedural success was 100%.
Stable angina (Canadian Class I-II) was the most common
indication for FFR (36%). In the group of acute coronary
syndrome, the non-culprit vessel was used for the current
trial. In 49.3% of the cases, LAD was the target FFR vessel
and in 41.3%, the lesion location was proximal (Table 2.)
89.5% of the patients were treated by dual antiplatelet ther-
apy (Table 3).
FFR measurements
There was no significant difference in the matched-
pairs comparison of intravenous adenosine infusion of
Table 1 Baseline characteristics and indiciations for
angiography
Patient demographics and clinical characteristics
Male (%) 77.3
Age (yrs) 66 ± 10
Body mass index (kg/m2) 26 ± 4
S-Creatinine (μmol/l) 87 ± 34
Previous MI (%) 33.3
Previous PCI (%) 43.2
Previous CABG (%) 11.8
Diabetes Mellitus (%) 20.2
Current Smoker (%) 14.5
Previous Smoker (%) 46.7
Hypertension (%) 76.0
Hyperlipidemia (%) 64.0
Caffeine consumption prior to procedure (%) 57.3
Indications for coronary angiography
Stable angina (%) 36.0
Unstable angina (%) 34.7
NSTEMI (%) 28.0
Diagnostic procedures (%) 1.7
Values are percentage and mean ± SD. MI myocardial infarction, PCI
percutaneous coronary intervention, CABG coronary artery bypass grafting,
NSTEMI non ST-elevation myocardial infarction
Table 2 Procedural characteristics
Coronary Angiography findings
Normal findings/Atheromatosis (%) 33.3
1-vessel disease (%) 29.4
2-vessel disease (%) 24.3
3-vessel disease (%) 13.0
Target vessel FFR
Left Main (%) 2.7
LAD (%) 49.3
1st Diagnonal branch (%) 4.0
LCx (%) 10.7
1st Marginal branch (%) 10.7
PLA (%) 2.6












Values are presented as %. LAD left anterior descending coronary artery,
LCx left circumflex coronary artery, PLA posterior-lateral artery, RCA right
coronary artery
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140 μg/kg/min versus 220 μg/kg/min (0.85 [0.79–0.90]
vs 0.85 [0.79–0.89], p = 0.24) (Fig. 1). In addition, high
dose adenosine showed a strong significant linear correl-
ation to standard dose (r = 0.86, slope = 0.89, p = <0.001)
(Fig. 2). In the Bland-Altman analysis, average of the dif-
ferences were -0.005 ± 0.03 (mean bias ± SD) [-0.07 to
0.06], [95% CI], (Fig. 3). In four patients (5.3%), the higher
dose of Adenosine caused a change in agreement due to
lowering FFR below the treatment threshold of 0.80
(0.85–0.79, 0.81–0.78, 0.81–0.79 and 0.81–0.79). The high
dose did not decrease FFR below 0.75 in any of the 75
cases. Thus, all changes remained in the borderline region.
Hemodynamic effects and patient discomfort
Mean arterial pressure and heart rate were similar
during infusion of the different adenosine doses. MAP:
Standard dose 7152 ± 178.2 versus high dose 6991 ±
346.7 AUC [arbitrary units], p = 0.34). Heart rate: Standard
dose 5488 ± 95.45 versus high dose 5602 ± 49.10 AUC
[arbitrary units] p = 0.11 (Fig. 4). Ten patients were
excluded from the second FFR measurement due to
atrioventricular block. In the remaining 75 patients, the
occurrence of atrioventricular block and bradyarrhyt-
mias was 5.3%. Patient maximal discomfort during
adenosine administration, measured by VAS, was
significantly higher in the dosage of 220 μg/kg/min (8.0
[5.0–9.0]) versus standard dose (5.0 [2.0–7.0]), p = <0.001
(Fig. 5).
Caffeine
A subgroup analysis was performed in the 43 patients
(57%) of the study population who reported caffeine
consumption ≤6h prior to FFR. In four patients (5.3%),
three from the caffeine group (4%) and one from the
control group (1.3%), high dose adenosine decreased
FFR from non-significant to borderline significant (0.78–
0.79). In the adenosine dosage of 140 μg/kg/min, FFR
was significantly higher in the caffeine group com-
pared to control (0.90 [0.83–0.93] versus 0.82 [0.75–
0.85], p = <0.001. In the high dose regime, there was a
similar trend but not significant (0.87 [0.81-0.91 versus
0.83 [0.77–0.88], p = 0.09) (Fig. 6). In a paired comparison
of caffeine consumers in the study population, FFR was
significantly higher in the group receiving standard dose
versus high dose adenosine (0.89 [0.83–0.93 vs 0.87 [0.81–
0.91], p = <0.001). In the control group, this difference
was reversed to significantly lower FFR in standard
dose compared to high dose (0.82 [0.75–0.85] vs 0.83
[0.77–0.89], p = 0.02) (Fig. 7). In three patients (4%), the
higher dose of adenosine caused a change in agreement
due to lowering FFR below the treatment threshold of
0.80 (0.85–0.79, 0.81–0.78, 0.81–0.79. The high dose
did not decrease FFR below 0.75 in any of the 75 cases.
Discussion
In this clinical trial we evaluated whether increased dose
adenosine in FFR would be associated with improved ac-
curacy of FFR compared to standard dose. No significant
differences in FFR values were found. Patient discomfort
was significant during administration of the higher dose.
Fig. 1 Wilcoxon matched-pairs signed rank test: There was no significant difference in the matched-pairs comparision of intravenous adenosine
infusion of 140 μg/kg/min versus 220 μg/kg/min (0.85 [0.79–0.90] vs 0.85 [0.79–0.89], p = 0.24)
Fig. 2 Linear regression model: High dose adenosine showed a
strong significant linear correlation to standard dose (r = 0.86,
slope = 0.89, p = <0.001)
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FFR measurements
Following the landmark trials FAME [4] and FAME2 [3]
the perception of assessment in non-critical coronary
stenosis have been altered. FFR became a powerful tool
not only for clinical practice, but also as the baseline
standard in clinical research [42, 43]. The critical pre-
requisite of hyperemia and the side effects following
systemic response of intravenous administration, have
urged development of different agents, routes and doses.
Even though different intravenous adenosine doses
during FFR been investigated in an earlier smaller study
[18], this present study concludes that their results
indeed are reproducible in a larger, clinical patient popu-
lation. Our results demonstrate that an increased dose
adenosine do not improve accuracy in FFR, but is associ-
ated with increased side effects. Different pharmaceutical
agents such as contrast media constitute an interesting
option without the side effects of vasodilatation. The
hyperemic capacity, mediated by osmosis, of contrast is
well known, but has in previous trials been inferior to
adenosine and papaverin [18]. Recent trials have demon-
strated non-inferiority between contrast media and adeno-
sine in the assessment of intermediate stenosis [17, 44],
but even though this may be an option in certain lesions,
there will still be need of adenosine-induced hyperemia in
some cases; hence the question of increased adenosine
doses needs to be adressed.
Fig. 3 Bland-Altman plot: In the Bland-Altman analysis, average of the differences was -0.005 ± 0.03 (mean bias ± SD) [−0.07 to 0.06], [95% CI]
Fig. 4 Mean arterial pressure and heart rate. There were no differences
in mean arterial pressure or in heart rate for standard dose versus
high dose
Fig. 5 VAS: Patient maximal discomfort during adenosine administration
was significantly higher in the dosage of 220 μg/kg/min (8.0 [5.0–9.0])
versus standard dose (5.0 [2.0–7.0]), p=<0.001
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Hemodynamic effects and patient discomfort
Adenosine interaction with A2A receptor mediates a
smooth muscle relaxation and thus a vasodilatation [45]. In
addition, adenosine regulates the autonomic innervation in
the heart by inhibition of the A1 receptors, and by that, ac-
complishes a negative chronotropic and dromotropic effect
in the conduction system [46, 47]. A concern in administra-
tion of adenosine, foremost in high dose regime, is that pa-
tients will develop adenosine induced systemic hypotension
and bradyarrhytmias. In a recent trial, the predictor of
hypotension during hyperemia was obesity and decreased
microcirculatory resistance [48]. Of the original enrollment
Fig. 6 a FFR were significantly higher in the caffeine group compared to control (p = <0.001). b In the high dose regime, there was a similar
trend but not significant
Fig. 7 a In a paired comparision of caffeine consumption, FFR was significantly higher in the group receiving standard dose versus high dose
(0.89 [0.83–0.93 vs 0.87 [0.81–0.91], p = <0.001). b In the control group, this difference was reversed to significantly lower FFR in standard dose
compared to high dose (0.82 [0.75–0.85] vs 0.83 [0.77–0.89], p = 0.02)
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of 87 patients, a total of 11.3% developed an atrioventricular
block during standard dose administration, and another
5.3% during high dose. Even though bradycardia usually is
not persistent, it may create discomfort, which is an
important reason why adenosine is prematurely terminated
during FFR and hence, the hyperemic effect remains
uncertain. Hypotension was uncommon in our study.
Hypothetically, patients with unstable angina/NSTEMI
and more complex lesions might be more prone to
develop hypotension. Also, we cannot rule out that the
intermittent monitoring of mean arterial pressure could
affect the hemodynamic measurements by terminating in-
fusions before severe hypotension develops. However, the
vasodilation capacity of adenosine, displayed by shortness
of breath, flushing and severe discomfort, was prominent.
This observation confirms that symptoms during adeno-
sine administration are not solely related to a systemic re-
sponse or coronary hemodynamic changes, but rather via
a direct effect on C-fibers in the lungs [49].
Caffeine
In this study, caffeine consumption was not randomized
or controlled, but in a secondary analysis we found
trends coherent with recent findings [31]. Matsumoto et
al. [30] investigated the effect of intravenous adenosine
doses of 140, 175 and 210 μg/kg/min in relation to papa-
verine during FFR. The effect of caffeine was less prom-
inent at 220 μg/kg/min. The increased FFR results in
patients on caffeine compared to controls in our trial
may indicate an attenuated adenosine effect by coffee.
However, the effect of increasing the dose of adenosine
was marginal.
Limitations of the study
The present study has some limitations. The higher dose
was always administered after the lower dose and a
cross-over design might have yielded different results.
However, this is the way adenosine is used in clinical
practice, and no one would consider starting with the
higher dose in all patients. The dose and timing of
caffeine consumption were neither randomized nor
controlled which might generate confounders. This was,
however, an exploratory secondary endpoint. In terms of
adenosine administration, we used a peripheral intraven-
ous line, which compared to a central vein might have a
slightly delayed systemic effect. However, we did flush
the adenosine infusion together with an infusion of
saline, a validated method to increase bioavailability and
making the possible delay negligible. Also, in the era of
transradial approach, a peripheral route for adenosin is
desirable, and has been demostrating similar results in
recent findings [50].
A considerable number of stable patients with type A
lesions were enrolled. Although this reflects standard
use of FFR in a real-life patient cohort, the possibility
that a population with more advanced disease would
have different results, cannot be ruled out.
Conclusion
Increased dose adenosine in fractional flow reserve
measurements did not lower the FFR but was associ-
ated with a significant increase of patient discomfort.
We did not observe persistent adenosine-induced
hypotension and the occurrence of bradyarrhytmias
were similar between standard dose and high dose.
Our findings do not support high dose adenosine in
the assessment of fractional flow reserve.
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